Shanghai releases measures to boost biomedical industry


Shanghai has released 32 measures to boost the development of its biomedical industry, which has been listed as a strategic emerging industry as part of the municipality's efforts to become a global city of excellence by 2035.
The measures, released by the municipal government in a document on Wednesday, listed the city's goal to raise the number of its clinical trial institutions to 80 and gather at least 20 research and development centers in biomedical innovation with international influence.
The document also includes ambitions to have more than 30 locally-developed new drugs and medical device products with core technological advantages registered each year.
"With the China (Shanghai) Pilot Free Trade Zone and the goal of building the city into a technological innovation center with global influence, Shanghai will promote its quality of pharmaceutical and medical device products by comparing with the highest standards internationally," reads the document.
For the purpose, the city will strive to readjust the supply system of drugs and medical devices and establish a regulation system to allow the public better access to new, advanced and affordable medical treatments, it continued.
One of the measures intended to build the city into a world-leader of innovative research and development in biomedicine is to encourage the increase of R&D investment.
- Fudan University unveils archaeology project to explore Silk Road heritage
- Chinese vice-premier urges all-out efforts to tackle Chikungunya fever outbreak
- China's ocean economy buckles pressure and posts 5.8% rise in marine GDP
- China's Qin Haiyang wins men's 200m breaststroke gold at World Aquatics Championships
- Across China: 80 years on, US youth carry the Flying Tigers' torch
- Shanghai's intl business zone offers visa-free entry to invited individuals